Islet transplant trial aims to free type 1 patients from severe lows
NCT ID NCT00679042
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 study tests whether transplanting insulin-making cells (islets) from donors can improve blood sugar control in people with type 1 diabetes who still have dangerous low blood sugar episodes despite intensive insulin therapy. About 21 participants receive the transplant along with lifelong anti-rejection drugs. The main goal is to see if one year after the transplant, patients have a normal blood sugar marker (HbA1c ≤ 6.5%) and no severe hypoglycemic events.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Illinois at Chicago Medical Center
Chicago, Illinois, 60612, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a smart pen take the guesswork out of insulin dosing?
- AI takes the wheel: could a smart algorithm optimize insulin pumps from home?
- Can a common diabetes pill make insulin therapy safer and more effective for type 1 diabetes?
- Real-World test of automated insulin system aims to improve blood sugar control for type 1 diabetes
- Can a wearable sensor help young people with type 1 diabetes tame blood sugar swings?
- Can a smartphone app help teens tame type 1 diabetes?